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Correspondence Normal pregnancy is associated with adaptive hemodynamic and vascular changes 72 including increased plasma volume and cardiac output and decreased vascular resistance, 73
such that blood pressure (BP) remains unchanged or is slightly decreased (59, 71) . Also, 74 changes in vasodilator substances such as nitric oxide (NO), prostacyclin (PGI 2 ), endothelium-75 derived hyperpolarizing factor (EDHF), and vascular endothelial growth factor (VEGF) 76 contribute to the vascular adaptations during normal pregnancy (75). These hemodynamic and 77 vascular changes lead to redistribution of blood flow in different maternal tissues and ensure 78 adequate blood supply to the growing fetus. 79
In 5-8% of pregnancies in the United States, ~8 million pregnancies worldwide, women 80 develop PE (74). PE is manifested as hypertension-in-pregnancy (HTN-Preg) and often 81 proteinuria. If untreated, PE could progress to eclampsia with severe hypertension, cerebral 82 edema and seizures. PE causes 15-20% of maternal deaths (8, 58, 63) , and is often 83 associated with intrauterine fetal growth restriction (IUGR), accounting for 10-15% of preterm 84 births (2, 63) . 85
Although PE is a major cause of maternal and fetal morbidity and mortality, the 86 mechanisms involved are not fully understood. Clinical observations in PE women have shown 87 reduction in brachial artery flow-mediated vasodilation, pointing to endothelial dysfunction as 88 an underlying mechanism (55, 79) . Because of the difficulty to perform mechanistic studies in 89 pregnant women, animal models of HTN-Preg have been developed (31, 40) . Studies in a rat 90 model of reduced uteroplacental perfusion pressure (RUPP) have shown some of the features 91 of PE including HTN, endothelial dysfunction and increased vascular reactivity (11, 19, 31) . 92
Also, studies in a rat model of gestational hypoxia have shown PE-like manifestations (81), 93
supporting that placental ischemia/hypoxia could be an initiating event in HTN-Preg. 94
In search of the intermediary mechanisms that link localized RUPP to systemic endothelial 95 and vascular dysfunction, studies have proposed that placental ischemia/hypoxia could trigger 96 the release of various bioactive factors in the maternal circulation (19, 34, 36, 38, 65, 80) . 97
Because of the marked fetal growth and placental vascularization during pregnancy, studies 98 have focused on possible changes in angiogenic factors such as VEGF and placental growth 99 factor (PlGF) in PE. VEGF gene expresses a family of proteins including VEGF-A, -B, -C, -D 100
and PlGF (29). VEGF-A, VEGF-B and PlGF bind to tyrosine kinase receptor Flt-1 (VEGFR-1) 101
and VEGF-A binds to VEGFR-2 (Flk-1 or KDR) to promote development of placental 102 vasculature (29). Measurements of circulating levels of VEGF in PE have not been consistent, 103
with studies showing decreased (56), unchanged (46, 48) or even increased levels in PE (7, 104 26, 72) . In comparison, PlGF has only 1/10th the affinity for VEGFR-1 compared to VEGF, but 105 its levels are ~40 times higher than VEGF during normal pregnancy (33). PlGF has four 106 alternatively spliced mRNA species (PIGF 1-4), and the circulating levels of its predominant 107 isoform PIGF-1 is decreased in PE (6, 72) . In contrast with angiogenic factors, soluble fms-like 108 tyrosine kinase-1 (sFlt-1, sVEGFR-1) is an anti-angiogenic factor expressed as an alternatively 109 spliced variant of VEGFR-1 that lacks both the transmembrane and cytoplasmic domains. sFlt-110 1 binds to VEGF and PlGF in the circulation and inhibits their action on cell surface VEGFR-1 111 (39) . Circulating levels of sFlt-1 are 10-fold higher in pregnant than non-pregnant women, 112 remain almost stable during the first and second trimester, then show an increase after the 113 36th week of gestation and throughout the third trimester (65). In PE, the increase in sFlt-1 114 levels is more pronounced (6, 29, 45, 72) , and the sFlt-1/PlGF ratio is higher in the circulation 115 of PE than normal pregnant women from the second trimester onwards (45, 51) . These 116 observations have led to the suggestion that an imbalance between angiogenic and anti-117 angiogenic factors could be an intermediary mechanism linking RUPP to HTN-Preg and PE. 118
Some studies have tested the effects of angiogenic factors in animal models of HTN-Preg. 119
One study showed that infusion of recombinant VEGF lowered BP and improved renal 120 function in rats with placental ischemia-induced HTN (21). Also, during the preparation of 121 this manuscript, a recently published study showed that infusion of recombinant PlGF 122 reduced BP and improved glomerular filtration rate in RUPP rats (68 Laboratories, Wilmington, MA) were housed in the animal facility and maintained on ad libitum 138 standard rat chow and tap water in 12 h light-dark cycle. On gestational day 14, some of the 139 rats were infused intravenously (IV) via a jugular vein catheter (PE-50) and osmotic minipump 140 with murine recombinant sFlt-1 (VEGF-R1/Flt-1 Fc Chimera, R&D Systems, Minneapolis, MN) 141 10 µg/kg/day for 5 days (Preg+sFlt-1); a dose that was previously shown to be sufficient to 142 cause HTN, proteinuria and glomerular endotheliosis (48). Previous studies projected a high 143 homology between murine and rat VEGFR-1 (4, 41), and other laboratories used murine 144 recombinant sFlt-1 in similar rat models of PE and did not report any immune response or 145 secondary effects (25, 48) . Other day 14 Preg rats underwent surgical procedure to reduce 146 uteroplacental perfusion pressure (RUPP) by banding the lower abdominal aorta above the 147 iliac bifurcation and the main uterine branches of the ovarian arteries as previously described 148 (3, 11, 19, 50) . Briefly, the abdominal aorta near the iliac bifurcation was carefully dissected 149 free of surrounding tissue and perivascular fat and separated from the vena cava. A blunt 150 plastic rod (OD, 0.3 mm) was placed parallel to the aorta, and a 4-0 silk braided ligature was 151 knotted twice around both the aorta and the adjacent plastic rod. Once taut, the rod was 152 carefully removed from the knotted ligature, thus creating a constrictive band (ID, 0.3 mm) and 153 reducing blood flow through the aorta. This procedure has been shown to reduce uterine 154 perfusion pressure in the gravid rat by ∼40% (14). Since compensation of blood flow to the 155 placenta occurs through an adaptive increase in ovarian blood flow (54), a blunt plastic rod 156 (OD, 0.1 mm) was used to place a ligature band (ID, 0.1 mm) on the main uterine branches of 157 both the right and left ovarian arteries. RUPP rats in which the banding procedure resulted in 158 maternal death or total reabsorption of the pups were excluded from data analyses. 159 RUPP rats were either nontreated or simultaneously infused via a jugular vein catheter 160 and osmotic pump with recombinant PIGF-1 (MBS696135, MyBiosource) 20 µg/kg/day for 5 161 days (RUPP+PlGF). A lower dose of PlGF (10 µg/kg/day) was also used, but was not sufficient 162 to decrease BP in RUPP rats. In other control experiments, some day 14 Preg rats were 163 infused IV for 5 days with sFlt-1 plus PlGF (Preg+sFlt-1+PlGF). Norm-Preg rats were sham 164 operated. All procedures were performed in accordance with the National Institutes of Health 165
Guide for the Care and Use of Laboratory Animals, and the guidelines of American 166
Physiological Society and the Harvard Medical Area Standing Committee on Animals. 167 168 Blood Pressure (BP). On day 19 of pregnancy, rats were anaesthetized with isoflurane, a PE-169 50 catheter was inserted in the carotid artery, and exteriorized at the back of the neck. The 170 rats were allowed to recover from anesthesia for at least 1 h. The carotid arterial catheter was 171 connected to a pressure transducer attached to an amplifier and pressure recorder (Living 172 System Instrumentation, Burlington, VT). BP in conscious rats was recorded for 1 min, every 173 20 min, over a period of 1 h and the average BP was measured (50). 174
175
Plasma sFlt-1 and PlGF. After measuring BP, blood samples were collected via the arterial 176 catheter into sterile heparin tubes (Tyco Healthcare, Mansfield, MA). Plasma was separated by 177 blood centrifugation at 2000×g for 10 min, and stored at -80°C for later use. Plasma sFlt-1levels were measured using rat sFlt-1 ELISA microplate kit (MBS2602003, MyBiosource) 179 according to the manufacturer instructions, with 0.05 ng/ml sFlt-1 sensitivity, intra-assay and 180
inter-assay precision, and coefficient of variability (CV) <12 %. The ELISA kit would detect 181 complexed sFlt-1 that was bound to PlGF and possibly VEGF in rat plasma. Plasma PlGF 182 levels were measured using rat PlGF ELISA microplate kit (MBS703282, MyBiosource) 183 according to the manufacturer instructions, with <0.78 pg/ml PlGF sensitivity, intra-assay and 184
inter-assay precision, and coefficient of variability (CV) <10 %. The ELISA kit would detect 185 both free PlGF and complexed PlGF that was bound to sFlt-1 in rat plasma. aprotinin and 20 μM 4-(2-aminoethyl)-benzenesulfonyl fluoride, using a 2-ml tight-fitting 254 homogenizer (Kontes Glass Co., Vineland, NJ). The tissue homogenate was centrifuged at 255 10,000×g for 2 min at 4°C, and the supernatant was collected. If the supernatant contained 256 floating debris, centrifugation was repeated at least two times to obtain a clear supernatant. 257
Protein concentration was determined using a protein assay kit (Bio-Rad, Hercules, CA). 258
Protein extracts (20 μg) were combined with an equal volume of 2X Laemmli loading buffer,boiled for 5 min, and size fractionated by electrophoresis on 8% SDS-polyacrylamide gels. 260
Proteins were transferred from the gel to a nitrocellulose membrane by electroblotting. 261
Membranes were incubated in 5% nonfat dried milk in phosphate buffered saline ( 
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Effect of altering sFlt-1/PlGF balance on maternal and fetal parameters 300
On gestational day 19, plasma sFlt-1 levels were higher in Preg+sFlt-1, RUPP and 301
RUPP+PlGF than Preg rats, and not different in RUPP+PlGF versus RUPP rats (Fig. 1A) . 302
Plasma PlGF was deceased in Preg+sFlt-1 and RUPP versus Preg rats, and was increased in 303
RUPP+PlGF versus RUPP to levels not different from those in Preg rats (Fig. 1B) . The sFlt-304 1/PlGF ratio was increased in Preg+sFlt-1 and RUPP versus Preg rats, and was restored in 305
RUPP+PlGF to levels lower than in RUPP rats and not different from Preg rats (Fig. 1C) . 306
On gestational day 19, BP was increased in Preg+sFlt-1 and RUPP versus Preg rats, and 307 was reduced in RUPP+PlGF versus RUPP to levels not significantly different from those in 308
Preg rats (Fig. 1D) . In other control experiments, BP was not significantly different in 309
Preg+sFlt-1+PlGF (107.3±2.7 mmHg) versus Preg rats (101.0±6.0 mmHg). 310 High KCI is known to stimulate Ca 2+ influx (53). In isolated endothelium-intact vessels of 319 all animal groups, KCI (96 mM) caused rapid followed by maintained contraction over a 10 min 320 time course. KCl contraction was greater in the aorta ( Fig. 2A) , carotid (Fig 2B) , mesenteric 321
( Fig. 2C ) and renal artery ( Fig. 2D ) of Preg+sFlt-1 and RUPP versus Preg rats. KCl 322 contraction was reduced insignificantly in the aorta, and significantly in the carotid, mesenteric 323
and renal artery of RUPP+PlGF versus RUPP rats, and to levels not significantly different from 324 the respective arteries of control Preg rats ( Fig. 2A-D) . No significant differences in KCl 325 contraction could be observed in endothelium-denuded aorta (Fig. 2E) , carotid (Fig 2F) , 326 mesenteric ( Fig. 2G ) and renal artery (Fig. 2H) In endothelium-intact vessels, Phe caused a concentration-dependent contraction that 334 was greater in the aorta (Fig. 3A) , carotid (Fig. 3B) , mesenteric ( Fig. 3C ) and renal artery 335 (Fig. 3D) of Preg+sFlt-1 and RUPP versus Preg rats. Phe contraction was reduced in the 336 aorta, carotid, mesenteric and renal artery of RUPP+PlGF versus RUPP, and to levels not 337 significantly different from the respective arteries of control Preg rats (Fig. 3A-D) . To test if the 338 enhanced contraction in Preg+sFlt-1 and RUPP versus Preg rats, and its reduction in 339
RUPP+PlGF versus RUPP are due to changes in α-adrenergic receptor sensitivity, Phecontraction was presented as % of maximum and Phe EC 50 was calculated. Phe contraction 341 as % max was not significantly different between the different animal groups in any of the 342 vessels tested (Fig. 3E-H between the different animal groups in any of the vessels tested (Fig. 3I-L We tested the role of endothelial NO-cGMP pathway in the differences in contraction 354 among the different animal groups and found that in endothelium-intact aorta (Fig. 4A) , carotid 355 (Fig. 4B) , mesenteric ( Fig. 4C ) and renal artery of Preg rats (Fig. 4D) , treatment with the NOS 356 inhibitor L-NAME or the guanylate cyclase inhibitor ODQ enhanced Phe contraction in grams. 357
Also, Phe contraction in grams was enhanced in endothelium-denuded versus intact vessels of 358
Preg rats (Fig. 4A-D, Table 1 ). Phe contraction in grams was enhanced to a less extent by L-359 NAME in the aorta (Fig. 4E) and by endothelium removal in the carotid artery (Fig. 4F) , and 360
was not affected by blockers of endothelial NO-cGMP or endothelium-removal in the 361 mesenteric (Fig. 4G) or renal artery (Fig. 4H) of Preg+sFlt-1 rats, suggesting that endothelial 362 function is compromised in Preg+sFlt-1 rats. Phe contraction in grams was also enhanced to a 363 less extent by endothelium blockers or removal in the aorta (Fig. 4I) , and by endothelium 364 removal in the carotid (Fig. 4J ) and mesenteric artery (Fig. 4K) , and was not affected by 365 endothelium blockers or removal in renal artery of RUPP rats (Fig. 4L, Table 1 ), suggesting 366 that endothelial function is also compromised in RUPP rats. Importantly, Phe contraction ingrams was enhanced by endothelium blockers or removal in the aorta (Fig. 4M) , carotid (Fig.  368   4N) , mesenteric ( Fig. 4O ) and renal artery (Fig. 4P) of RUPP+PlGF rats to levels that closely 369 mimic those observed during similar treatment of respective vessels from control Preg rats, 370 suggesting restored functional endothelium. Of note, the differences in vascular reactivity 371 between groups were less apparent in vessels treated with NO-cGMP blockers and in 372 endothelium-denuded vessels ( Table 1) , suggesting that the differences in vascular reactivity 373 are likely due to differences in the endothelial NO-cGMP pathway. Also, measurement of Phe 374 contraction in L-NAME or ODQ treated or endothelium-denuded vessels as fold change of the 375 control contraction in nontreated intact vessels, showed greater fold change in Phe contraction 376
in Preg compared with Preg-sFlt-1 or RUPP rats, and in RUPP+PlGF versus RUPP (Table 1) , 377
supporting differences in endothelial NO-cGMP activity among the different animal groups. 378
When Phe contraction was presented as %max and EC 50 was calculated the Phe 379 response did not change significantly by L-NAME or ODQ treatment or endothelium removal in 380 the aorta, carotid and renal artery of the different animal groups (Fig. 5, Table 1 ), suggesting 381 little change in sensitivity to Phe. Phe was more potent in inducing contraction in ODQ treated 382 mesenteric vessels of all animal groups and in L-NAME treated mesenteric vessels of Preg-383 sFlt-1 rats (Fig. 5, Table 1 ) 384
When the Phe response was presented as % of KCl contraction, treatment with L-NAME 385 or ODQ enhanced Phe contraction in the aorta, carotid, mesenteric and renal artery of Preg 386 rats ( Fig. 6A-D, Table 1 ). Only treatment with L-NAME enhanced Phe contraction as % of KCl 387 contraction in mesenteric artery (Fig. 6G) , and endothelium NO-cGMP blockers or removal did 388 not affect the Phe response in the aorta (Fig. 6E) , carotid (Fig. 6F) or renal artery of 389
Preg+sFlt-1 rats (Fig. 6F) , Also, only ODQ enhanced Phe contraction as % of KCl contraction 390 in the aorta (Fig. 6I) , but endothelium NO-cGMP blockers or removal did not affect Phe 391 response in the carotid (Fig. 6J) , mesenteric (Fig. 6K) or renal artery of RUPP rats (Fig. 6L) . 392
On the other hand, treatment with L-NAME or ODQ or endothelium removal enhanced Phe 393 contraction as % of KCl in the aorta, carotid, mesenteric and renal artery of RUPP+PlGF rats( Fig. 6M-P, Table 1 ). Of note, the enhancement of Phe contraction as % of KCl in 395
RUPP+PlGF was more pronounced and exceeded that in RUPP rats in carotid artery treated 396 with L-NAME or endothelium-denuded, and in mesenteric artery treated with ODQ (Table 1) . 397
Also, measurement of the changes in Phe contraction in L-NAME or ODQ-treated or 398 endothelium-denuded vessels as fold change of the control contraction in nontreated intact 399 vessels showed greater fold change in Phe contraction as % of KCl in Preg compared with 400
Preg-sFlt-1 and RUPP, and in RUPP+PlGF versus RUPP rats ( In endothelium-intact vessels, ACh-induced relaxation was reduced in the aorta (Fig. 7A) , 405 carotid (Fig 7B) , and renal artery (Fig. 7D) of Preg+sFlt-1 and RUPP versus Preg rats, 406
suggesting that sFlt-1 infusion in Preg rats causes reduction in endothelium-dependent 407 relaxation similar to that in RUPP rats. ACh relaxation was enhanced in RUPP+PlGF versus 408 RUPP and to levels similar to those in control Preg rats, suggesting that restoring sFlt-1/PlGF 409 balance improves endothelium-dependent relaxation in HTN-Preg rats. Maximal ACh 410 relaxation was similar in the mesenteric artery of all animal groups (Fig. 7C) . ACh 411 concentration-response curve was also shifted to the right, and ACh was less potent in the 412 aorta, carotid, mesenteric, and renal artery of Preg+sFlt-1 and RUPP versus Preg rats, 413
suggesting impaired endothelium-dependent relaxation. Importantly, the sensitivity shift in ACh 414 relaxation was corrected in RUPP+PlGF versus RUPP rats and to levels comparable to those 415 in control Preg rats ( Table 1) . 416
ACh relaxation was completely blocked by the NOS inhibitor L-NAME or guanylate 417 cyclase inhibitor ODQ in the aorta, carotid and renal artery of all animal groups (Fig. 8) . ACh 418 relaxation was only partially blocked by L-NAME and ODQ in the mesenteric artery of all 419 groups. ACh relaxation was abolished by endothelium removal in all vessels tested from all 420 anima groups (Fig. 8) , supporting a role of endothelial NO-cGMP relaxation pathway.
422
Effect of altering sFlt-1/PlGF balance on vascular eNOS levels and NO production 423
Western blot analysis revealed that total eNOS (Fig. 9A) and activated p-eNOS (Fig. 9B)  424 were reduced in aortic tissue homogenate of Preg+sFlt-1 and RUPP versus Preg rats, and 425
were enhanced in RUPP+PlGF versus RUPP and to levels similar to those in control Preg rats. 426
Further analysis of p-eNOS/total eNOS ratio showed that it was not significantly different 427
between Preg (0.64±0.26), Preg+sFlt-1 (1.03±0.32), RUPP (1.13±0.59) and RUPP+PlGF rats 428 (0.89±0.31), suggesting that the observed differences in p-eNOS are mainly due to changes in 429 eNOS expression. In endothelium-intact aortic rings (Fig. 9C) , nitrate/nitrite production under 430
10
-9 M ACh was lower in Preg+sFlt-1 and RUPP versus Preg rats and higher in RUPP+PlGF 431 versus RUPP. A less distinct trend in nitrate/nitrite production under 10 -9 M ACh was observed 432 in mesenteric artery rings, and the differences in nitrate/nitrite production under 10 -9 M ACh 433 were not significant among the different groups (Fig. 9D) . ACh caused concentration-434 dependent increases in nitrate-nitrite production that were reduced in aorta and mesenteric 435 artery of Preg+sFlt-1 and RUPP versus Preg rats, and was enhanced in RUPP+PlGF versus 436 RUPP and to levels similar to those in control Preg rats (Fig. 9C, 9D ). These data suggest that 437 the observed effects of sFlt-1 and PlGF treatment involve long-term changes in eNOS 438 expression which in turn affect the extent of eNOS phosphorylation and activation and NO 439 production. 440
441
Effect of altering sFlt-1/PlGF balance on endothelium-independent relaxation 442
In endothelium-denuded vessels, the exogenous NO donor sodium nitroprusside (SNP) 443 caused concentration-dependent relaxation that was not significantly different in the aorta (Fig.  444 10A), carotid (Fig 10B), mesenteric (Fig. 10C) or renal artery (Fig. 10D) The present study assessed the extent of sFlt-1/PlGF imbalance and vascular dysfunction 451 in HTN-Preg RUPP rats, and showed how inducing a comparable sFlt-1/PlGF imbalance by 452 infusing sFlt-1 in Preg rats was sufficient to increase BP and vascular contraction and 453 decrease endothelium-dependent relaxation, eNOS expression/activity and NO production to 454 levels similar to those n RUPP rats. Using these guiding measurements, the present study 455 then demonstrated that restoring sFlt-1/PlGF balance by infusing PlGF in HTN-Preg RUPP 456 rats reversed the decrease in endothelial NO-cGMP and the increases in vascular contraction 457
and BP and brought them to levels comparable to those in control Preg rats. 458 459
sFlt-1/PlGF imbalance and increased vasoconstriction in HTN-Preg 460
Inadequate trophoblast invasion of spiral arteries and the ensuing uteroplacental 461 insufficiency are important events in the pathogenesis of PE (17, 31, 63) . Studies in RUPP and 462 hypoxic pregnant rats have supported placental ischemia as an initiating mechanism of HTN-463 Preg and IUGR (11, 19, 31, 81) . In agreement, the present study showed increased BP and 464 decreased litter size and pup weight in RUPP vs. Preg rats. We assessed the extent of 465 vascular dysfunction in RUPP rats and found increases in contraction to the α-adrenergic 466 receptor agonist Phe in four major systemic vessels with relevance to PE. The increased aortic 467 contraction is important as it supplies all the vascular beds in the systemic circulation. The 468 increased carotid artery contraction could affect the cephalic circulation and in turn contribute 469 to the cerebral manifestations in PE. The increased contraction in the mesenteric vascular 470 bed, which constitute a major portion of peripheral resistance (9), could contribute to the 471 increased BP. The increased renal vasoconstriction could contribute to the changes in 472 glomerular filtration rate, plasma volume and protein excretion in PE. These observations 473 support changes in vascular reactivity as an important mechanism of the increased BP and 474 other manifestations in HTN-Preg RUPP rats (50, 53).PE has also been postulated to involve angiogenic imbalance with a tilt towards anti-476 angiogenic factors (19, 38, 39, 45, 48) . The observed increase in plasma sFlt-1 levels and sFlt-477 1/PlGF ratio in RUPP rats is consistent with reports that circulating sFlt-1 and the sFlt-1/PlGF 478 ratio are elevated in PE women (6, 45, 51, 72, 73) , and in RUPP and other animal models of 479 19, 23, 60, 67) . The sFlt-1/PlGF ratio can be modulated by not only an increase 480 in sFlt-1, but also a decrease in PlGF. The present observation that plasma levels of PlGF are 481 decreased in RUPP vs. Preg rats is consistent with reports that PlGF levels are decreased in 482 PE women (6, 51, 72) and in RUPP and DOCA-salt rat models of 19) . 483
We assessed the pressor and vascular effects of inducing a sFlt-1/PlGF imbalance 484 comparable to that in RUPP rats and found that infusing sFlt-1 in Preg rats was associated 485 with increases in BP. This is consistent with reports that Preg rats treated with sFlt-1 develop 486
HTN, proteinuria, and marked glomerular endotheliosis (25, 48). The increase in BP in 487
Preg+sFlt-1 rats was associated with increases in Phe contraction, suggesting that circulating The increases in vascular contraction in RUPP and Preg+sFlt-1 rats and their reversal in 497 and RUPP rats and the reversal of this increase in RUPP+PlGF rats could be explained by 504 common changes in endothelium-dependent relaxation pathways. Phe contraction was 505 enhanced in endothelium-denuded vessels of Preg and RUPP+PlGF rats, but to a less extent 506 in Preg+sFlt-1 and RUPP rats. Also, the differences in Phe and KCl contraction among the 507 different rat groups were observed in intact vessels, but were absent when the endothelium 508 was removed. Thus it is plausible that the enhanced vascular contraction in RUPP and 509
Preg+sFlt-1 rats is due to reduction in endothelium-derived relaxing factors, and the reduced 510 vascular hyper-reactivity in RUPP+PlGF rats could be due to improved endothelial function, 511 making it necessary to further examine endothelial function in the different animal groups. 512 513
sFlt-1/PlGF balance and mechanisms of vascular relaxation in HTN-Preg 514
ACh caused less relaxation in the aorta, carotid and renal artery and was less potent in all 515 vessels of RUPP and Preg+sFlt-1 vs. Preg rats, suggesting that sFlt-1/PlGF imbalance is an 516 important factor in the reduced endothelium-dependent relaxation in HTN-Preg. These data 517 are in agreement with previous studies showing a decrease in ACh relaxation or sensitivity to 518
ACh in the aorta (11) and mesenteric artery of HTN-Preg RUPP rats (50, 78). ACh relaxation 519 was improved in the aorta, carotid and renal artery and ACh was more potent in all vessels of 520 RUPP+PlGF vs. RUPP rats, suggesting that restoring sFlt-1/PlGF balance reverses the 521 decrease in endothelium-dependent relaxation mechanisms in HTN-Preg. 522
The endothelium releases vasodilator substances such as NO, PGI 2 , and EDHF. NO 523 diffuses into VSM where it increases cGMP, which in turn causes relaxation by decreasing 524 VSM [Ca 2+ ] i and Ca 2+ sensitivity of the contractile proteins (27, 42). Our previous studies in the 525 aorta, carotid and renal artery of virgin rats showed that ACh relaxation was associated with 526 increased NO production and was inhibited by L-NAME, suggesting a role of endothelial NO-527 cGMP (62). In contrast, in the mesenteric artery, a large portion of ACh relaxation remained in 528 the presence of L-NAME and the COX inhibitor indomethacin, and was abolished by the K + 529 channel blocker TEA, suggesting a role of EDHF (49). The enhanced vascular contraction in 530 RUPP and Preg+sFlt-1 vs. Preg rats appears to involve reduction in endothelial NO-cGMP 531 because the NOS inhibitor L-NAME and guanylate cyclase inhibitor ODQ enhanced Phe 532 contraction markedly in Preg rats but to a less extent in RUPP and Preg+sFlt-1 rats, 533
suggesting that an endothelial NO-cGMP pathway that reduces contraction during pregnancy 534 is compromised in HTN-Preg rats. Of note, blocking endothelial NO-cGMP pathway did not 535 affect the sensitivity to Phe in the aorta, carotid and renal artery, while Phe was more potent in 536 inducing contraction in ODQ-treated mesenteric artery of all animal groups (Fig. 5, Table 1) , 537
suggesting increased sensitivity to changes in cGMP in the mesenteric circulation. The present 538 data also suggest that sFlt-1 may downregulate endothelial NO-cGMP in HTN-Preg because: 539 1) In all animal groups, ACh relaxation was abolished by endothelium removal in all vessels 540 tested, and was blocked by L-NAME or ODQ, completely in the aorta, carotid and renal artery 541 and partially in the mesenteric artery. 2) Total eNOS and activated p-eNOS were reduced in 542 the aorta of Preg+sFlt-1 and RUPP rats vs. Preg rats. 3) ACh-induced NO production was 543 reduced in aorta and mesenteric artery of Preg+sFlt-1 and RUPP rats vs. Preg rats.
4) 544
Vascular relaxation to the NO donor SNP was not different in Preg+sFlt-1 and RUPP rats vs. 545
Preg rats, further suggesting a role of endothelial NO-cGMP in the observed changes in 546 vascular relaxation rather than differences in the ability of VSM to relax. 547
Our experiments with PlGF to counterbalance sFlt-1 in RUPP rats provide evidence that 548 the reduced BP and vascular contraction in RUPP+PlGF involve improvement in endothelial 549 NO-cGMP because: 1) Endothelium-removal or treatment with L-NAME or ODQ enhanced 550
Phe contraction in RUPP+PlGF to levels similar to those in RUPP rats. 2) ACh-induced 551 relaxation was enhanced in RUPP+PlGF vs. RUPP and to levels similar to those in control 552
Preg rats. 3) Total eNOS and p-eNOS were augmented in the aorta of RUPP+PlGF vs. RUPP 553 rats. 4) ACh nitrate/nitrite production was enhanced in the aorta and mesenteric artery of 554
RUPP+PlGF vs. RUPP rats. 5) Vascular relaxation to the NO donor SNP was not different in 555
RUPP+PlGF vs. RUPP rats, suggesting that the differences are not related to differences inthe ability of VSM to relax, and further suggesting a role of endothelial NO-cGMP in the 557 observed changes in vascular relaxation. 558
The changes in the vascular relaxation pathways are particularly important in the 559 mesenteric circulation as it contributes substantially to BP regulation and could be one of the 560 main sites altered in HTN-Preg. Similar to the observations in the aorta, carotid and renal 561 artery, ACh was less potent in causing relaxation in the mesenteric artery of RUPP and 562
Preg+sFlt-1 vs. Preg rats and more potent in RUPP+PlGF vs. RUPP rats. Also, similar to the 563 observation in the aorta, ACh-induced nitrate/nitrite production was reduced in RUPP and 564
Preg+sFlt-1 vs. Preg rats and enhanced in RUPP+PlGF vs. RUPP rats. However, in contrast 565 with other vascular beds, maximal ACh relaxation was not different in the mesenteric artery of 566 the different animal groups. Also, in contrast with the complete blockade of ACh relaxation in 567 the aorta, carotid and renal artery by the NOS inhibitor L-NAME and guanylate cyclase 568 inhibitor ODQ, ACh relaxation of the mesenteric artery was only partially inhibited by blockade 569 of the NO-cGMP pathway. These differences emphasize how the changes in angiogenic 570 factors during pregnancy could affect different signaling pathways in different vascular beds. In 571 this respect, EDHF has been suggested as an important vasodilator in mesenteric arteries (16) 572 and may explain the observed L-NAME and ODQ-resistant component of ACh-induced 573 relaxation. However, we have previously shown that blockade of K + channels with 574 tetraethylammonium (TEA) or apamin+TRAM-34 caused similar inhibition of ACh-induced 575 relaxation in mesenteric microvessels of both Preg and RUPP rats, suggesting an intact and 576 equally active EDHF-dependent relaxation pathway (49). 577
The effects of antiangiogenic and angiogenic factors on the NO-cGMP pathway could be 578 due to their general effects on angiogenesis and in turn endothelial cell development and 579 signaling, as well as direct effects on endothelial cell signaling. Studies in human umbilical vein 580 endothelial cells (HUVECs) cocultured with hypoxic human trophoblasts have shown an 581 increase in sFlt-1 and a decrease in VEGF in cell-conditioned medium that are associated with 582 endothelial cell dysfunction and decreased eNOS synthesis (82). VEGF has been shown toregulate angiogenesis, endothelial cell proliferation, and vascular permeability (29, 65 induces L-NAME sensitive vasorelaxation in rat aorta (12). Furthermore, PlGF causes 593 vasodilation and increases cGMP production in the pulmonary vasculature of perfused piglet 594
lungs (28), supporting a role of PlGF in activating the NO-cGMP vasodilation pathway. 595
596

Other observations/considerations 597
The observed antagonism between sFlt-1 and PlGF in the setting of sFlt-1/PlGF 598 imbalance, increased BP and vascular hyper-reactivity in RUPP rats could involve sFlt-1 599 sequestering of endogenous PlGF and VEGF, which would in turn lead to a decrease in 600 plasma free PIGF and VEGF. In the present study, we used PlGF to restore sFlt-1/PlGF 601 balance in RUPP rats. A previous elegant study used recombinant VEGF infusion at 90 or 180 602 µg/kg/day to restore angiogenic balance, and showed that it lowered BP and improved renal 603 function in rats with placental ischemia-induced HTN (21). We used PlGF instead of VEGF 604 because: 1) Most studies show decreased PlGF levels in PE (6, 45, 72), while measurements 605 of VEGF have not been consistent with studies showing decreased (56), not changed (46, 48) 606 or even increased levels in PE (7, 26, 72) . 2) In PE, there is an increase in circulating sFlt-1 607 that binds to VEGF, thus total (bound and unbound) VEGF levels could be elevated or not 608 changed in most forms of PE and PE-like models. On the other hand, the angiogenic 609 imbalance is induced because the free, unbound form of VEGF is decreased, due to thesequestering, neutralizing effect of sFlt-1 (5). 3) VEGF may stimulate sFlt-1 production in the 611 placenta through an action on VEGFR-2 (15). VEGF levels are controlled at the maternal-fetal 612 interface, partly through feedback modulation of sFlt-1, in order to prevent damage to the 613 placenta or fetus by excess VEGF (15), and dysregulation of this feedback mechanism may 614 complicate the measurement of angiogenic and anti-angiogenic levels. 4) PlGF is specific for 615 VEGFR-1 and its soluble form sFlt-1, while VEGF also binds to VEGFR-2, causing increased 616 vascular permeability and edema (43) and could promote cancer partly through its angiogenic 617 effects (61). 618
Also, while preparing this manuscript, a recently published study showed that infusion of 619 recombinant human PlGF at 180 μg/kg/day abolished placental ischemia-induced HTN-Preg in 620 rats (68). We used a smaller dose 20 µg/kg/day of PlGF because 1) Using our guiding 621 measurements of sFlt-1 and PlGF levels in Preg, RUPP and Preg+sFlt-1 rats, we aimed to 622 reduce the sFlt-1/PlGF ratio to levels that closely resemble those in control Preg rats. 2) The 623 present dose of PlGF was sufficient to counterbalance sFlt-1 because the sFlt-1/PlGF ratio 624 was decreased in RUPP+PlGF vs. RUPP rats, and to levels similar to those in control Preg 625 rats.
3) The present dose of PlGF was sufficient to block the effects of sFlt-1 as BP was 626 reduced in RUPP+PlGF rats and in Preg+sFlt-1+PlGF rats to levels similar to those in control 627
Preg rats. A lower dose of PlGF (10 µg/kg/day) was not sufficient to decrease BP in RUPP 628 rats. 4) PlGF reversed the increases in Phe contraction and the decreases in ACh relaxation, 629 eNOS expression/activity and NO production in RUPP rats to levels similar to those in control 630
Preg rats. 5) We avoided higher doses of PlGF as excess PlGF may induce microvascular 631 abnormalities (32) or developmental anomalies (69). 6) The angiogenic/anti-angiogenic 632 balance is tightly controlled by feedback mechanisms, and excess PlGF could drive a 633 feedback increase in sFlt-1 to maintain the sFlt-1/PlGF ratio. 634
The present study showed that blocking the endothelial NO-cGMP relaxation pathway by 635 endothelium removal or treatment with the NOS inhibitor L-NAME or guanylate cyclase 636 inhibitor ODQ enhanced Phe contraction not only in grams but also as % of KCl contraction.
Assuming that KCl contraction is mainly due to Ca 2+ influx (53), then the enhanced Phe 638 contraction in endothelium-denuded and NO-cGMP-blocked vessels is likely due to activation 639 of Ca 2+ -sensitization pathways such as protein kinase C (PKC) or Rho-kinase (13, 64). While 640
Phe contraction as % of KCl was not different in endothelium-intact vessels from the different 641 groups (Fig. 3) , the enhancement of Phe contraction by endothelium removal or NO-cGMP 642 blockade was more apparent in Preg than Preg+sFlt-1 or RUPP and in RUPP+PlGF than 643 RUPP rats (Fig. 8, Table 1 ). The differences in Ca 2+ sensitization pathways were not observed 644 in endothelium-intact vessels because they were likely obscured by increased NO-cGMP, and 645 only with endothelium removal or blockade of NO-cGMP the enhanced contraction 646 mechanisms could be manifested. This is supported by reports that NO and cGMP reduce 647 [Ca 2+ ] i (42), and cGMP-dependent protein kinase causes phosphorylation and inhibition of 648 myosin light chain kinase and Ca 2+ sensitization pathways (64). Whether the differences in the 649 Ca 2+ sensitization mechanisms of VSM contraction are due to changes in sFlt-1 or PlGF is 650 unclear and needs to be further examined. 651
In addition to endothelium-derived vasodilators, the endothelium releases contracting 652 factors such as endothelin-1 (ET-1). Studies have shown an association between sFlt-1/PlGF 653 imbalance and the levels of ET-1 in PE (77). Also, we have shown increases in ET-1 induced 654 vasoconstriction in mesenteric vessels of RUPP rats (50), and whether the vascular responses 655 to ET-1 are altered with changes in sFlt-1 and PlGF in HTN-Preg should to be tested. 656
The present data should be interpreted with caution as there are forms of HTN-Preg that 657 may not be represented by the RUPP model such as the Dahl salt-sensitive HTN-Preg rat and 658 the catechol-O-methyltransferase deficient mice (23, 30) . Also, other anti-angiogenic factors 659 may be released and affect vascular function in PE. Soluble endoglin (sEng) is an anti-660 angiogenic protein that binds transforming growth factor-β1 and inhibits its effects on signaling, 661 eNOS activation and vasodilation (29). Serum sEng levels are higher in PE and HELLP 662 syndrome compared with normal Preg women (76), and in RUPP vs. normal Preg rats (20) . 663
The role of sEng in the changes in vascular function in HTN-Preg should be further examined.
Increases in other bioactive factors such as the cytokines TNF-α and interleukin-6, reactive 665 oxygen species, hypoxia inducible factor, angiotensin type 1 receptor autoantibodies have also 666 been observed in PE women and in animal models of [34] [35] [36] 38, 65, 80) , and 667 future studies should examine the integrated role of these bioactive factors in the changes in 668 vascular function in HTN-Preg and PE. 669
670
Perspective 671 The present study showed that similar to RUPP rats, inducing sFlt-1/PlGF imbalance by 672 infusing sFlt-1 in Preg rats increases BP and vascular contraction and decreases endothelial 673 NO-cGMP-mediated vasodilation, supporting that endothelial dysfunction is a central 674 mechanism in HTN-Preg and that sFlt-1 is an important intermediary factor linking placental 675 ischemia to decreased endothelial function in HTN-Preg. In this respect, counterbalancing sFlt-676 1 by infusing PlGF enhanced eNOS expression and NO-mediated vasodilation and reduced 677 vascular contraction and BP in HTN-Preg RUPP rats. Currently, delivery of the baby and 678 placenta is the only effective measure to reverse PE. The present findings could be useful in 679 designing new approaches for the management of HTN-Preg and PE. For example, activators 680 of NO-cGMP could counteract the sFlt-1-induced decrease in eNOS expression/activity and 681 NO production in HTN-Preg. This is in line with reports that the phosphodiesterase-5 (PDE-5) 682 inhibitor sildenafil, which enhances and prolongs the effects of cGMP, ameliorates HTN-Preg 683 in RUPP and Dahl salt-sensitive rats (18, 22) . Another approach is extracorporeal removal of 684 circulating sFlt-1 from PE patients. Although this procedure decreases the sFlt-1/PlGF ratio 685 and could improve PE symptoms and prolong pregnancy (70), it may require advanced 686 apheresis equipment and highly trained clinical staff that may only be feasible in large medical 687
centers. An alternative approach is to infuse PlGF to restore sFlt-1/PlGF balance and reverse 688 the maternal vascular hyper-reactivity and increased BP in PE. Preterm birth is another 689 undesirable outcome of PE, and could be the only measure to prevent the progress to 690 eclampsia. Our data in RUPP and Preg+sFlt-1 rats support that sFlt-1/PlGF imbalance isassociated with decreased litter size and pup weight. Importantly, RUPP+PlGF rats showed 692 improved litter size and pup weight when compared with RUPP rats, suggesting that PlGF not 693 only counterbalances the effects of sFlt-1 in the maternal circulation, but could also promote 694 fetal growth and development and prolong pregnancy in HTN-Preg and PE. An important 695 question is how PlGF would improve fetal parameters in the face of fixed RUPP. We propose 696 that RUPP is only an initiating event that triggers a cascade of biochemical and pathological 697 events that lead to the different maternal and fetal manifestations associated with 698 preeclampsia. The initial physically-induced reduction in uterine perfusion pressure in the 699 RUPP rat is thought to cause initial placental ischemia/hypoxia which would increase the 700 The vessels were stimulated with increasing concentrations of Phe, and the contractile 1004 response was presented in grams (g). Data represent means±SEM, n=5-9. *P<0.05, L-NAMEcontraction was measured. Data represent means±SEM, n=6-9. *P<0.05, Preg+sFlt-1 or38 059 
